Two Rhode Island cannabinoid research laboratories are suing the DEA for standing in the way of what they consider to be the crucial development of pharmaceutical-grade cannabis products for use in clinical trials for the treatment of Multiple Sclerosis and Huntington's Disease.
The companies argue that the DEA has long passed the deadlines to issue a decision and has delayed progress from the beginning, say scientists from the labs in question MMJ BioPharma Cultivation Inc., MMJ International Holdings Corp., which now say it's time for legal action.
